- About Bayer
- Contact Us
- HCP Login
- About Bayer
- Contact Us
- HCP Login
Bayer launches a new tool in the fight against malaria
- Johannesburg, March 6, 2019 – With nearly half of the world’s population at risk of contracting malaria, primarily in sub Saharan Africa, stepping up the fight against the disease has never been a more pressing challenge. Bayer is rising to this challenge as it launches a new Indoor Residual Spray (IRS), Fludora® Fusion which is set to make great strides in the fight against malaria.
According to the World Health Organisation, there were 219 million cases of malaria in 2017, up from 217 million cases in 2016[i]. In Southern Africa alone, more than 16 000 cases resulting in 110 deaths were reported by the end of October in 2018. This is more than the average over the 10-year period between 2007 and 2016, which was estimated at 7 600 cases per year[ii].
“We know that insecticide resistance remains one of the biggest threats to eradicating malaria largely because of our reliance on a very limited number of insecticides that are effective in vector control interventions against malaria carrying mosquitos. In the context of this urgent need for new modes of action in malaria vector control, Fludora® Fusion represents a major step forward in eradicating malaria, says Dr. Jacqueline M. Appelgate, Head of of Global Vegetable Seeds & Environmental Science at Bayer.
Added to the challenge of insecticide resistance, Appelgate says, “It is also of great concern that the prevalence of malaria areas have expanded with low or very low malaria transmission starting to appear in some districts previously regarded as malaria-free areas in South Africa and elsewhere.”
Bayer’s field trials, in an unprecedented 16 African countries, has proven Fludora® Fusion to not only be effective against more than a dozen resistant strains of mosquitos, but results also show that it remains effective for up to 12 months after application.
With such an effective tool, Appelgate explains, “We know that investing in the development of malaria fighting tools will only be successful if accessible to those in need. This is why Bayer is committed to providing public health programmes with Fludora® Fusion that is not only proven but is also effective. In this way, a healthier, better life is more accessible to everyone.”
Bayer has been a mainstay in global malaria prevention strategy for over 60 years by making continued investments in effective vector control solutions, recognising that improvement and innovations in these tools are crucial to saving lives and ensuring a healthier future. Appelgate concludes, “We’re excited by the potential that Fludora® Fusion represents to help prevent new malaria infections and is a major milestone in our pursuit of a malaria-free furture.”
ii. SaNTHNet: Seasonal malaria increase in progress 11 December 2018
About Fludora® Fusion
Fludora® Fusion is the first product for Indoor Residual Spraying (IRS) of houses to combine two unrelated modes of action – clothianidin and deltamethrin. The combination approach provides optimum effectiveness against malaria vectors under conditions of insecticide resistance. For more information, please see
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.co.za
Mobile +27 82 8732423
Head of Communications for Southern Africa
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments